BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 208 filers reported holding BRIDGEBIO PHARMA INC in Q2 2021. The put-call ratio across all filers is 1.95 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $426,554 | +363.6% | 14,608 | +43.2% | 0.00% | – |
| Q2 2022 | $92,000 | -13.2% | 10,201 | -0.7% | 0.00% | – |
| Q1 2022 | $106,000 | -94.0% | 10,273 | -91.5% | 0.00% | -100.0% |
| Q4 2021 | $1,759,000 | -71.8% | 120,460 | -4.9% | 0.00% | -66.7% |
| Q3 2021 | $6,242,000 | +13.8% | 126,665 | +39.1% | 0.00% | 0.0% |
| Q2 2021 | $5,484,000 | +13.2% | 91,039 | +9.2% | 0.00% | 0.0% |
| Q1 2021 | $4,844,000 | +507.0% | 83,346 | +616.5% | 0.00% | +200.0% |
| Q4 2020 | $798,000 | +439.2% | 11,632 | +208.6% | 0.00% | – |
| Q3 2020 | $148,000 | -24.5% | 3,769 | -38.0% | 0.00% | – |
| Q2 2020 | $196,000 | +684.0% | 6,082 | +499.8% | 0.00% | – |
| Q1 2020 | $25,000 | -81.5% | 1,014 | -73.6% | 0.00% | – |
| Q4 2019 | $135,000 | +45.2% | 3,846 | -11.2% | 0.00% | – |
| Q3 2019 | $93,000 | -65.6% | 4,332 | -56.7% | 0.00% | – |
| Q2 2019 | $270,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |